Papers by Lorenzo Sabatelli
Advances in Therapy
Bookmarks Related papers MentionsView impact
Value in Health, 2021
Bookmarks Related papers MentionsView impact
Value in Health, 2020
Bookmarks Related papers MentionsView impact
Social Science Research Network, Dec 1, 2013
Bookmarks Related papers MentionsView impact
Value in Health, Nov 1, 2013
Bookmarks Related papers MentionsView impact
Value in Health, Jun 1, 2021
Bookmarks Related papers MentionsView impact
Value in Health, Nov 1, 2014
Bookmarks Related papers MentionsView impact
The European Physical Journal B - Condensed Matter, 2002
Bookmarks Related papers MentionsView impact
Value in Health, 2022
Bookmarks Related papers MentionsView impact
Value in Health, Dec 1, 2020
Bookmarks Related papers MentionsView impact
Annals of Hematology, Jul 11, 2023
Bookmarks Related papers MentionsView impact
Advances in Therapy, May 19, 2023
Bookmarks Related papers MentionsView impact
Value in Health, 2022
Bookmarks Related papers MentionsView impact
Value in Health, Oct 1, 2017
Bookmarks Related papers MentionsView impact
Annals of Hematology, May 12, 2023
Bookmarks Related papers MentionsView impact
Clinical Lymphoma Myeloma and Leukemia
Bookmarks Related papers MentionsView impact
Value in Health, 2019
Bookmarks Related papers MentionsView impact
Clinical Lymphoma Myeloma and Leukemia
Bookmarks Related papers MentionsView impact
Annals of Hematology
RE-MIND2 (NCT04697160) compared patient outcomes from the L-MIND (NCT02399085) trial of tafasitam... more RE-MIND2 (NCT04697160) compared patient outcomes from the L-MIND (NCT02399085) trial of tafasitamab+lenalidomide with those of patients treated with other therapies for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are autologous stem cell transplant ineligible. We present outcomes data for three pre-specified treatments not assessed in the primary analysis. Data were retrospectively collected from sites in North America, Europe, and the Asia Pacific region. Patients were aged ≥18 years with histologically confirmed DLBCL and received ≥2 systemic therapies for DLBCL (including ≥1 anti-CD20 therapy). Patients enrolled in the observational and L-MIND cohorts were matched using propensity score-based 1:1 nearest-neighbor matching, balanced for six covariates. Tafasitamab+lenalidomide was compared with polatuzumab vedotin+bendamustine+rituximab (pola-BR), rituximab+lenalidomide (R2), and CD19-chimeric antigen receptor T-cell (CAR-T) therapies. The primary endpoint ...
Bookmarks Related papers MentionsView impact
Journal of Clinical Oncology
7560 Background: Tafasitamab (tafa) + lenalidomide (LEN) demonstrated efficacy in adult patients ... more 7560 Background: Tafasitamab (tafa) + lenalidomide (LEN) demonstrated efficacy in adult patients (pts) with R/R DLBCL ineligible for autologous stem-cell transplant in the pivotal Phase II study L-MIND (NCT02399085) and received accelerated approval in the United States in 2020 and conditional marketing authorization in Europe and Canada in 2021 in this setting. RE-MIND2 (NCT04697160), an observational, retrospective cohort study, compared pt outcomes from L-MIND with matched pt cohorts treated with other NCCN/ESMO recommended therapies. Methods: Methodology for RE-MIND2 has been presented previously. Hypothesis-generating analyses were conducted for pt subgroups of number of extranodal sites (ENS) (0–1 vs ≥2) and elevated lactate dehydrogenase (LDH) (yes vs no) in matched cohorts of pts receiving tafa + LEN vs systemic therapies pooled (STP), polatuzumab vedotin + bendamustine + rituximab (pola-BR), rituximab + LEN (R2), and CD19 CAR-T therapies (CAR-T). The primary endpoint was ov...
Bookmarks Related papers MentionsView impact
Uploads
Papers by Lorenzo Sabatelli